New Immunotherapy for Childhood Neuroblastoma
Toward Translation of an Immunotherapeutic Nanomedicine for Neuroblastoma
['FUNDING_R01'] · VANDERBILT UNIVERSITY · NIH-11136913
This research is developing a new type of immunotherapy to help children with advanced, high-risk neuroblastoma.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | VANDERBILT UNIVERSITY (nih funded) |
| Locations | 1 site (Nashville, UNITED STATES) |
| Trial ID | NIH-11136913 on ClinicalTrials.gov |
What this research studies
Neuroblastoma is a serious childhood cancer that is often difficult to treat, and current therapies can be very harsh. This project is working on a new treatment called STING-activating nanoparticles (STANs), which are tiny particles designed to boost the body's own immune system to fight cancer cells. Researchers are refining these particles and studying how they work in models, aiming to make them ready for use in patients. The goal is to find better, less toxic ways to treat this aggressive cancer.
Who could benefit from this research
Good fit: This research is focused on developing therapies for children diagnosed with advanced, high-risk neuroblastoma.
Not a fit: Patients without neuroblastoma or those with other types of cancer would not directly benefit from this specific treatment approach.
Why it matters
Potential benefit: If successful, this new immunotherapy could offer a more effective and less toxic treatment option for children battling high-risk neuroblastoma.
How similar studies have performed: While neuroblastoma has been challenging to treat with many existing immunotherapies, this approach with STING-activating nanoparticles is a novel strategy being advanced for this specific cancer.
Where this research is happening
Nashville, UNITED STATES
- VANDERBILT UNIVERSITY — Nashville, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WILSON, JOHN TANNER — VANDERBILT UNIVERSITY
- Study coordinator: WILSON, JOHN TANNER
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.